Cargando…
Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics
Background: The global pharma sector is fast shifting from generics to biologics and biosimilars with the first approval in Europe in 2006 followed by US approval in 2015. In the form of Hepatitis B vaccine, India saw its first recombinant biologics approval in 2000. Around 20% of generic medication...
Autores principales: | Panda, Sunita, Singh, Puneet Kumar, Mishra, Snehasish, Mitra, Sagnik, Pattnaik, Priyabrata, Adhikary, Sanjib Das, Mohapatra, Ranjan K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865573/ https://www.ncbi.nlm.nih.gov/pubmed/36679955 http://dx.doi.org/10.3390/vaccines11010110 |
Ejemplares similares
-
Nanoadjuvants:
Promising Bioinspired and Biomimetic
Approaches in Vaccine Innovation
por: Desai, Dhruv N., et al.
Publicado: (2023) -
Emerging monkeypox cases amid the ongoing COVID-19 pandemic in the Indian subcontinent: A probable healthcare challenge for South East Asia
por: Mohapatra, Ranjan K., et al.
Publicado: (2022) -
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022) -
Deadly endemic zoonotic disease Ebola re-emerges in the democratic Republic of Congo amid the ongoing COVID-19: are we prepared from lessons learnt? – Correspondence
por: Mohapatra, Ranjan K., et al.
Publicado: (2022) -
Potential threat and possible global spread of the novel SARS-CoV-2 Omicron subvariants including XBB.1.16 during the Indian Premier League 2023: strict implementation of traveller guidelines suggested
por: Mohapatra, Ranjan K., et al.
Publicado: (2023)